Topics

Biosimilars May Be More Cost Effective in Follicular Lymphoma Treatment

19:00 EST 8 Nov 2019 | Cancer Networks

Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.

Original Article: Biosimilars May Be More Cost Effective in Follicular Lymphoma Treatment

NEXT ARTICLE

More From BioPortfolio on "Biosimilars May Be More Cost Effective in Follicular Lymphoma Treatment"

Quick Search

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...